The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The effect of pre-existing CHIP on toxicity, outcomes, and inflammatory profiles in CAR-T recipients
Giulia Rappa, PhD, LMU Munich, Munich, Germany, discusses the findings of a study investigating the impact of pre-existing clonal hematopoiesis of indeterminate potential (CHIP) on CAR T-cell therapy outcomes in patients with lymphoma and multiple myeloma (MM). The findings suggest that CHIP is not associated with increased immunotoxicity and inflammatory serum signatures. While no differences were observed between CHIP and non-CHIP groups in terms of CAR-T-mediated toxicities and survival, CHIP patients with TP53 mutations exhibited a distinct inflammatory profile and a trend towards lower progression-free survival (PFS) and overall survival (OS). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
